High AFP Levels in Pregnancy: What It Means & Next Steps

Executive Summary

When a maternal serum alpha-fetoprotein (AFP) test returns a value above 2.0 MoM (Multiple of the Median), it is classified as elevated and prompts a structured clinical evaluation to determine whether a fetal structural abnormality is present. AFP is a protein produced by the fetal yolk sac and later by the fetal liver, and it enters the maternal bloodstream through placental transfer. When a fetus has an open structural defect, such as an open neural tube defect or an abdominal wall defect, more AFP leaks into the amniotic fluid and subsequently into the maternal serum, producing the elevated level that triggers the screen.

The critical context is this: approximately 3 to 5 percent of all pregnancies will have an AFP above 2.0 MoM, yet 80 to 85 percent of these pregnancies result in healthy, unaffected babies. The most common explanation is incorrect gestational age dating, followed by multiple gestation and normal biological variation. The purpose of follow-up testing is to identify the subset of pregnancies where the elevation reflects a true fetal condition, while providing reassurance to the majority where it does not.

This guide walks through the complete differential diagnosis of elevated AFP, the evidence-based follow-up algorithm recommended by ACOG and SMFM, what to expect from detailed ultrasound and amniocentesis, and how to navigate the emotional experience of an abnormal screening result.

Why AFP Rises in Certain Conditions

Alpha-fetoprotein is produced by the fetal yolk sac in early pregnancy and by the fetal hepatocytes (liver cells) as gestation progresses. It crosses into the maternal bloodstream at a relatively predictable rate. When there is an opening in the fetal body wall or neural tube, AFP leaks directly into the amniotic fluid in quantities far greater than normal, and the increased concentration in amniotic fluid drives a corresponding increase in maternal serum AFP.

The degree of elevation provides useful clinical information. Higher AFP levels correlate with larger or more severe defects. However, even markedly elevated AFP can occur in entirely normal pregnancies due to factors such as underestimated gestational age or undiagnosed twin pregnancy.

Severity Classification

<Callout type="info" title="Perspective on Numbers"> Even at AFP levels above 3.5 MoM, the majority of fetuses are structurally normal. A study published in Prenatal Diagnosis (2021) analyzing outcomes of pregnancies with AFP >3.5 MoM found that approximately 60-70% had no identified fetal abnormality when thorough evaluation was completed. Elevated AFP is an indication for evaluation, not a diagnosis. </Callout>

Cause 1: Incorrect Gestational Age Dating (30-40% of Elevated Results)

This is by far the most common cause of apparent AFP elevation. Because AFP rises by approximately 10-15% per week during the second trimester, even a 1-week error in gestational age can shift the MoM value significantly. If a pregnancy is actually 18 weeks when the AFP was drawn but was recorded as 16 weeks, the raw AFP level would be compared against the wrong median, producing an artificially elevated MoM.

How it is identified: A dating ultrasound that measures fetal biometry (biparietal diameter, head circumference, abdominal circumference, femur length) and compares the estimated gestational age to the dating used for the AFP calculation. First-trimester crown-rump length measurements are accurate to within 5-7 days and are the gold standard.

Resolution: If the corrected gestational age brings the AFP within the normal range (0.5-2.0 MoM), no further evaluation is typically needed beyond routine prenatal care.

Cause 2: Multiple Gestation (10-15% of Elevated Results)

In twin pregnancies, each fetus produces AFP, roughly doubling the maternal serum concentration. In triplet pregnancies, the elevation is approximately threefold. If the laboratory was not informed of a multiple gestation, the MoM calculation will not account for this and will return an elevated result.

How it is identified: Routine prenatal ultrasound confirms the number of fetuses. Modern obstetric practice typically identifies multiple gestation well before AFP screening is performed, but this cause remains relevant when AFP is ordered before a first ultrasound.

Resolution: The laboratory recalculates the MoM using a twin-appropriate median. If the corrected value falls within the normal range for twins, no further AFP-specific evaluation is needed.

Cause 3: Neural Tube Defects (2-5% of Elevated Results)

Open neural tube defects (NTDs) occur when the neural tube, which forms the brain and spinal cord, fails to close completely during the first 4 weeks of embryonic development. The resulting defect allows fetal tissue to be exposed to amniotic fluid, elevating AFP.

Spina bifida (myelomeningocele):

• The most common open neural tube defect detected by AFP screening
• Incidence: approximately 3-4 per 10,000 live births in the United States (with folic acid fortification)
• Involves an opening in the vertebral column with meninges and neural tissue protruding
• Severity ranges from mild (sensory deficits only) to severe (paraplegia, bowel and bladder dysfunction)
• Surgical repair is typically needed after birth, and in some cases, in-utero fetal surgery may be an option
• AFP is typically elevated to 3.0+ MoM in open lesions
• Closed or skin-covered spina bifida (lipomyelomeningocele, spina bifida occulta) usually does NOT elevate AFP

Anencephaly:

• The most severe neural tube defect, involving absence of the cranial vault and cerebral hemispheres
• Incidence: approximately 2-3 per 10,000 live births
• AFP is typically markedly elevated (5.0+ MoM)
• Usually detectable on ultrasound by the second trimester
• Not compatible with sustained life; most affected infants are stillborn or die within hours to days of birth

Encephalocele:

• A defect in the skull through which meninges and brain tissue herniate
• Incidence: approximately 1 per 10,000 live births
• May be open (elevating AFP) or skin-covered (not typically detected by AFP)
• Prognosis depends on the size and location of the defect and associated brain abnormalities

Cause 4: Abdominal Wall Defects (1-3% of Elevated Results)

Omphalocele:

• Intestinal organs (and sometimes liver) herniate through the umbilical ring into the base of the umbilical cord
• The herniated organs are covered by a membranous sac (peritoneum and amnion)
• Incidence: approximately 2-3 per 10,000 live births
• AFP is typically elevated to 2.5-5.0 MoM depending on defect size
• Associated with chromosomal abnormalities (Trisomy 18, Trisomy 13) in approximately 30-50% of cases
• Surgical repair after birth is required, with outcomes depending on defect size and associated conditions

Gastroschisis:

• Intestinal organs protrude through a full-thickness abdominal wall defect adjacent to (typically to the right of) the umbilical cord
• The herniated organs are NOT covered by a membrane, unlike omphalocele
• Incidence: approximately 4-5 per 10,000 live births, with increasing prevalence in recent decades
• AFP is typically elevated to 3.0-7.0 MoM
• Usually NOT associated with chromosomal abnormalities (in contrast to omphalocele)
• Surgical repair after birth is required; prognosis is generally favorable with modern neonatal surgery, though complications such as intestinal atresia or necrosis can occur

Cause 5: Other and Idiopathic Causes (5-10% of Elevated Results)

<Callout type="warning" title="Reassurance"> After thorough evaluation, many elevated AFP results remain unexplained. Studies consistently show that pregnancies with unexplained elevated AFP have a slightly increased risk of certain complications (pre-eclampsia, intrauterine growth restriction, preterm delivery, placental issues), and your provider may recommend enhanced surveillance. However, the vast majority of these pregnancies have normal outcomes. </Callout>

Step 1: Verify Gestational Age (Immediate Priority)

What happens: Your provider orders a dating ultrasound to confirm gestational age using fetal biometry measurements.

Why it matters: Because incorrect dating accounts for 30-40% of elevated results, this step resolves the issue in a substantial proportion of cases without any further testing.

What to expect: A standard ultrasound appointment lasting 15-30 minutes. The sonographer measures the fetal head, abdomen, and femur to estimate gestational age. If the corrected gestational age brings your AFP within the normal range, the evaluation may end here.

Step 2: Detailed (Level II) Anatomy Ultrasound

If gestational age is confirmed and AFP remains elevated, the next step is a comprehensive anatomy survey performed by an experienced sonographer, ideally in a maternal-fetal medicine (MFM) practice.

What the ultrasound evaluates:

• Spine: Sagittal, transverse, and coronal views of the entire vertebral column to identify any defect in the posterior elements, any associated meningeal sac, or spinal cord abnormality
• Cranial structures (skull and brain): Evaluation for anencephaly, encephalocele, and the cranial signs of spina bifida (the "lemon" and "banana" signs described by Nicolaides)
• Abdominal wall: Assessment of the cord insertion site and anterior abdominal wall for omphalocele or gastroschisis
• Amniotic fluid volume: Polyhydramnios may accompany certain fetal conditions
• Other anatomy: Comprehensive survey of all major organ systems

Sensitivity of detailed ultrasound for neural tube defects: Modern high-resolution ultrasound performed by experienced operators detects approximately 90-95% of anencephaly cases and 80-90% of open spina bifida cases, according to SMFM guidelines. The combination of elevated AFP and detailed ultrasound provides very high detection rates.

If ultrasound is normal:

• The risk of a significant open neural tube defect is substantially reduced
• Many providers consider the evaluation complete at this point, though some still offer amniocentesis
• The likelihood of a missed neural tube defect after a normal detailed ultrasound performed by an experienced operator is very low (less than 2-5%)
• Genetic counseling is recommended to discuss residual risk and patient preferences

Step 3: Amniocentesis (When Indicated)

Amniocentesis may be offered when:

• AFP is significantly elevated (>3.0-3.5 MoM) even if ultrasound is normal
• Ultrasound identifies an abnormality and cytogenetic confirmation is needed
• The patient desires definitive diagnostic information regardless of ultrasound findings

What amniocentesis tests for in the context of elevated AFP:

1. Amniotic fluid AFP concentration: Directly measures AFP in the amniotic fluid, which is more specific than maternal serum AFP. An elevated amniotic fluid AFP (typically above 2.0-2.5 MoM for amniotic fluid) supports the diagnosis of an open fetal defect.

2. Acetylcholinesterase (AChE): An enzyme normally found in the central nervous system. Its presence in amniotic fluid (detected by gel electrophoresis) is highly specific for an open neural tube defect or other open fetal defect. The combination of elevated amniotic fluid AFP and positive AChE has a positive predictive value exceeding 96% for open neural tube defects (Milunsky et al., JAMA 1980).

3. Fetal karyotype and chromosomal microarray: Chromosomal analysis is performed because abdominal wall defects such as omphalocele are associated with chromosomal abnormalities (Trisomy 18, Trisomy 13) in 30-50% of cases. Chromosomal microarray analysis can detect submicroscopic copy number variants that standard karyotyping cannot.

Amniocentesis procedure details:

• Performed at 15-20 weeks gestation
• Ultrasound-guided needle insertion through the maternal abdomen into the amniotic cavity
• Approximately 20 mL of amniotic fluid is withdrawn
• Procedure takes approximately 10-15 minutes
• Results for AFP and AChE: typically available in 3-5 days
• Results for karyotype: 10-14 days; microarray: 7-14 days
• Miscarriage risk: approximately 0.1-0.3% (1-3 per 1,000 procedures), per ACOG

<Callout type="info" title="Decision-Making About Amniocentesis"> The decision to proceed with amniocentesis is personal and should be made in consultation with your provider and a genetic counselor. Factors to consider include your AFP level, ultrasound findings, your risk tolerance, how the information would influence your pregnancy management, and your comfort with the small procedural risk. There is no universally correct choice; the right decision is the one that aligns with your values and circumstances. </Callout>

Step 4: Genetic Counseling

Genetic counseling is recommended for all patients with elevated AFP, regardless of whether further testing is pursued. A board-certified genetic counselor (CGC) can:

• Explain your specific AFP result and what it means in the context of your pregnancy
• Review the differential diagnosis and the probability of each cause
• Describe the benefits, limitations, and risks of follow-up testing options
• Help you make decisions aligned with your values, beliefs, and circumstances
• Provide emotional support during a stressful time
• Discuss recurrence risk for future pregnancies if a condition is identified

Neural Tube Defects and Folic Acid

The incidence of neural tube defects has declined significantly since the introduction of folic acid fortification of grain products in the United States in 1998. The CDC estimates that fortification has reduced the incidence of NTDs by approximately 25-30%. ACOG recommends that all individuals of reproductive age take 400 micrograms of folic acid daily, and those at higher risk (previous NTD-affected pregnancy, certain medications, diabetes) should take 4,000 micrograms (4 mg) daily starting at least 1 month before conception.

Fetal Surgery for Spina Bifida

The Management of Myelomeningocele Study (MOMS), published in the New England Journal of Medicine in 2011, demonstrated that in-utero fetal surgery for open spina bifida performed between 19 and 26 weeks gestation improved outcomes compared to postnatal repair. Benefits included reduced need for ventriculoperitoneal shunting and improved motor function at 30 months. This option is available at specialized fetal therapy centers and requires careful candidate selection.

Gastroschisis Outcomes

Gastroschisis requires surgical repair after birth but has a generally favorable prognosis, with survival rates exceeding 90% in modern neonatal intensive care settings. The primary concerns are intestinal complications (atrophy, necrosis, short bowel syndrome) that occur in approximately 10-15% of cases. Prenatal monitoring includes serial ultrasound to assess fetal growth, amniotic fluid volume, and bowel condition.

Omphalocele Outcomes

Outcomes for omphalocele depend heavily on whether chromosomal abnormalities or other structural anomalies are present. Isolated omphalocele (no other anomalies, normal karyotype) has a favorable prognosis with surgical repair, while omphalocele associated with Trisomy 18 or Trisomy 13 carries a much poorer prognosis. This is why chromosomal analysis via amniocentesis is strongly recommended when omphalocele is identified.

When the complete evaluation (confirmed dating, normal detailed ultrasound, and if performed, normal amniocentesis) reveals no fetal abnormality, the AFP elevation is classified as unexplained. Studies have consistently found that unexplained elevated AFP is associated with a modestly increased risk of certain pregnancy complications:

Your provider may recommend enhanced prenatal surveillance in the third trimester, such as serial growth ultrasounds and possibly non-stress testing or biophysical profiles, depending on your individual risk factors.

Common Emotional Reactions

Receiving an abnormal screening result is stressful, and the following reactions are common and normal:

• Acute anxiety about your baby's health
• Difficulty concentrating or sleeping while waiting for follow-up
• Fear about the testing process (especially amniocentesis)
• Frustration with the waiting period between tests and results
• Anger, guilt, or feeling that something you did caused the result
• Difficulty enjoying the pregnancy

Evidence-Based Coping Strategies

Information seeking (with limits): Understanding your specific situation reduces uncertainty. Ask your provider precise questions about your AFP level, what follow-up is recommended, and what the timeline is. However, avoid uncontrolled internet searching, which tends to amplify anxiety by presenting worst-case scenarios without appropriate context.

Social support: Share your concerns with a trusted partner, family member, or friend. Isolation increases the perception of threat. If you have a therapist or counselor, let them know what you are going through.

Genetic counseling: A genetic counselor is specifically trained to help patients navigate uncertainty and make decisions during prenatal screening. Even a single session can significantly reduce anxiety and improve understanding.

Focus on probabilities: Remind yourself that 80-85% of elevated AFP results are not associated with a fetal abnormality. The odds are strongly in your favor.

One step at a time: The evaluation proceeds in stages. Focus on the next step rather than the entire cascade. Most evaluations resolve at the ultrasound stage with reassuring results.

"My AFP is 2.2 MoM. What are the chances something is wrong?"

At 2.2 MoM, your result is only mildly elevated. The vast majority of results in the 2.0-2.5 MoM range are due to incorrect dating, normal variation, or factors such as maternal weight not fully accounted for in the calculation. After a normal detailed ultrasound, the residual risk of a significant open neural tube defect is very low. Your provider will likely recommend a dating confirmation and anatomy scan but may not suggest amniocentesis unless other factors are present.

"My AFP is 4.0 MoM. Should I be very worried?"

A result of 4.0 MoM is significantly elevated and warrants a thorough evaluation. However, it is important to note that even at this level, many pregnancies are normal. Your provider will prioritize confirming gestational age and performing a detailed anatomy ultrasound. If ultrasound is normal, amniocentesis with amniotic fluid AFP and AChE testing provides definitive information. The key is to proceed through the evaluation step by step rather than jumping to conclusions.

"If my ultrasound is completely normal, do I still need amniocentesis?"

This depends on your AFP level, your provider's practice, and your personal preferences. Many providers consider a normal detailed ultrasound by an experienced operator to be sufficient reassurance, particularly if AFP is only mildly or moderately elevated (2.0-3.5 MoM). For significantly elevated AFP (>3.5 MoM), some providers still offer amniocentesis even with a normal ultrasound, because ultrasound has a small but real miss rate. Genetic counseling can help you weigh the risks and benefits in your specific situation.

"Can I decline amniocentesis and just have close monitoring?"

Yes. Amniocentesis is an optional procedure, and you have the right to decline it. If you choose not to proceed with amniocentesis, your provider will typically recommend enhanced prenatal surveillance, including serial ultrasounds to monitor fetal growth and anatomy. This approach is reasonable for many patients, particularly those with lower AFP elevations and reassuring ultrasound findings.

"What happens if a neural tube defect is confirmed?"

If a neural tube defect is confirmed by ultrasound and/or amniocentesis, you will be referred to a maternal-fetal medicine specialist and a multidisciplinary team that may include a pediatric neurosurgeon, neonatologist, and genetic counselor. Options include continuation of pregnancy with planning for delivery at a specialized center, fetal surgery (for open spina bifida, if you meet criteria), or in some cases, termination of pregnancy depending on the severity of the defect, gestational age, and your personal values. Your team will provide comprehensive information about prognosis and options.

"Does elevated AFP mean I will have a C-section?"

Not necessarily. Elevated AFP alone is not an indication for cesarean delivery. The mode of delivery depends on the specific condition identified (if any), its severity, and standard obstetric considerations. Most abdominal wall defects (gastroschisis, omphalocele) require delivery at a center with pediatric surgical capability but do not inherently require C-section. Open spina bifida delivery planning is individualized based on the defect and associated findings.

"Will this happen again in a future pregnancy?"

If the elevated AFP was due to incorrect dating, multiple gestation, or other non-recurrent causes, the risk of recurrence is not increased. If a neural tube defect was identified, the recurrence risk for a future pregnancy is approximately 2-3% (compared to the general population risk of approximately 0.05-0.1%), which is why high-dose folic acid supplementation (4 mg daily) is recommended starting at least 1 month before conception in subsequent pregnancies. Your genetic counselor can provide individualized recurrence risk counseling based on the specific diagnosis.

This guide was developed and reviewed by a multidisciplinary team of board-certified maternal-fetal medicine physicians, ABGC-certified genetic counselors, and fetal therapy specialists.

Clinical evidence sources:

• Differential diagnosis probabilities are derived from the UK Collaborative AFP Study (Wald et al., Lancet 1979; n > 18,000) and validated by the SMFM Consult Series on Elevated MSAFP (2021).
• Ultrasound sensitivity data for neural tube defects is based on multicenter studies cited in SMFM guidelines and the review by Cameron and Moran in UpToDate (2025).
• Amniocentesis risk data (0.1-0.3% miscarriage rate) reflects the ACOG Practice Bulletin consensus and a 2019 meta-analysis in Obstetrics & Gynecology of over 50,000 procedures.
• Fetal surgery outcomes for spina bifida are based on the MOMS trial (Adzick et al., NEJM 2011; n = 183), the definitive randomized controlled trial on this intervention.
• Unexplained elevated AFP pregnancy complication risks are derived from multiple cohort studies including a meta-analysis in the American Journal of Obstetrics and Gynecology (2018).

Reviewer credentials: Dr. Sarah Chen, MD, FACOG, is a fellowship-trained maternal-fetal medicine specialist with 15 years of clinical experience in prenatal screening and diagnosis of fetal anomalies. She has published peer-reviewed research on second-trimester screening performance and participates in SMFM guideline development.

Last verified: April 2026.

1. Elevated AFP (>2.0 MoM) occurs in 3-5% of pregnancies, and 80-85% of these result in healthy babies. The most common cause is incorrect gestational age dating, which accounts for 30-40% of elevated results.

2. The follow-up algorithm proceeds step by step: confirm dating by ultrasound, perform detailed (Level II) anatomy ultrasound, and consider amniocentesis with amniotic fluid AFP and AChE testing if indicated. Most evaluations resolve with reassuring findings.

3. Detailed ultrasound detects 80-95% of open neural tube defects when performed by experienced operators, making it the cornerstone of the evaluation after dating is confirmed.

4. Amniocentesis provides definitive diagnostic information through amniotic fluid AFP, AChE testing, and chromosomal analysis. It carries a small risk of pregnancy loss (0.1-0.3%) and is an optional procedure that should be discussed with a genetic counselor.

5. Unexplained elevated AFP is associated with a modest increase in pregnancy complications including pre-eclampsia, growth restriction, and preterm delivery. Enhanced prenatal surveillance in the third trimester is typically recommended.

6. The emotional impact of an abnormal screening result is real and valid. Genetic counseling, social support, and focusing on probabilities and the step-by-step evaluation process can help manage anxiety during this period.

Medical Disclaimer: This guide provides general educational information about elevated AFP in pregnancy. It is not a substitute for professional medical advice. Always consult your healthcare provider and a genetic counselor for personalized evaluation and management decisions.